The TGF-β/Smad pathway has long been recognized as the ‘master regulator’ driving renal fibrosis, making it a prime target for drug development, exemplified by the Smad3 inhibitor Specific Inhibitor of Smad3 (SIS3) (Zhang et al., 2018). The gene discussed is SMAD3; the disease is renal fibrosis.